XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-50.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XTLB vs AEYE
Revenue, margins, valuation, and 5-year total return — side by side.
AEYE
AudioEye, Inc.
Software - Application
Market Cap$100M
5Y Perf.-4.5%
XTLB vs AEYE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XTLB | AEYE |
|---|---|---|
| Industry | Biotechnology | Software - Application |
| Market Cap | $294K | $100M |
| Revenue (TTM) | $451K | $40M |
| Net Income (TTM) | $-1M | $-3M |
| Gross Margin | 26.4% | 78.3% |
| Operating Margin | -481.6% | -7.9% |
| Total Debt | $138K | $721K |
| Cash & Equiv. | $371K | $5M |
XTLB vs AEYE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XTLB
AEYE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| XTL Biopharmaceutic… (XTLB) | 100 | 49.8 | -50.2% |
| AudioEye, Inc. (AEYE) | 100 | 95.5 | -4.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XTLB vs AEYE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AEYE leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
XTLB
XTL Biopharmaceuticals Ltd.
The Income Pick
XTLB is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.71
- EPS growth 45.5%
- Lower volatility, beta 1.71, Low D/E 2.5%, current ratio 0.61x
Best for: income & stability and growth exposure
AEYE
AudioEye, Inc.
The Long-Run Compounder
AEYE carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 102.2% 10Y total return vs XTLB's -87.3%
- 14.5% revenue growth vs XTLB's -173.2%
- -7.6% margin vs XTLB's -227.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AEYE | 14.5% revenue growth vs XTLB's -173.2% |
| Quality / Margins | AEYE | -7.6% margin vs XTLB's -227.7% |
| Stability / Safety | XTLB | Beta 1.71 vs AEYE's 2.29, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | AEYE | -27.9% vs XTLB's -50.9% |
| Efficiency (ROA) | AEYE | -9.5% ROA vs XTLB's -17.7%, ROIC -42.4% vs -54.1% |
XTLB vs AEYE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
XTLB vs AEYE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAEYELAGGINGXTLB
XTLBXTL Biopharmaceutical…
1leads
AEYEAudioEye, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AEYE5/5
Valuation MetricsMultiples, price ratios, and targets
XTLB2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AEYE6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
AEYE5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AEYE leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
AEYE is the larger business by revenue, generating $40M annually — 89.4x XTLB's $451,000. Profitability is closely matched — net margins range from -7.6% (AEYE) to -2.3% (XTLB).
| Metric | XTLBXTL Biopharmaceut… | AEYEAudioEye, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $451,000 | $40M |
| EBITDAEarnings before interest/tax | -$1M | -$504,000 |
| Net IncomeAfter-tax profit | -$1M | -$3M |
| Free Cash FlowCash after capex | $0 | $2M |
| Gross MarginGross profit ÷ Revenue | +26.4% | +78.3% |
| Operating MarginEBIT ÷ Revenue | -4.8% | -7.9% |
| Net MarginNet income ÷ Revenue | -2.3% | -7.6% |
| FCF MarginFCF ÷ Revenue | -3.7% | +5.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +7.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +20.0% | +29.0% |
AEYE leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
XTLB leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | XTLBXTL Biopharmaceut… | AEYEAudioEye, Inc. |
|---|---|---|
| Market CapShares × price | $293,767 | $100M |
| Enterprise ValueMkt cap + debt − cash | $60,767 | $96M |
| Trailing P/EPrice ÷ TTM EPS | -0.28x | -32.36x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.65x | 2.49x |
| Price / BookPrice ÷ Book value/share | 0.05x | 20.91x |
| Price / FCFMarket cap ÷ FCF | — | — |
XTLB leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
AEYE leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-48 for AEYE. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to AEYE's 0.15x. On the Piotroski fundamental quality scale (0–9), AEYE scores 4/9 vs XTLB's 3/9, reflecting mixed financial health.
| Metric | XTLBXTL Biopharmaceut… | AEYEAudioEye, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -25.5% | -47.8% |
| ROA (TTM)Return on assets | -17.7% | -9.5% |
| ROICReturn on invested capital | -54.1% | -42.4% |
| ROCEReturn on capital employed | -50.7% | -17.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.15x |
| Net DebtTotal debt minus cash | -$233,000 | -$5M |
| Cash & Equiv.Liquid assets | $371,000 | $5M |
| Total DebtShort + long-term debt | $138,000 | $721,000 |
| Interest CoverageEBIT ÷ Interest expense | -13.31x | -2.79x |
AEYE leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
AEYE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AEYE five years ago would be worth $3,977 today (with dividends reinvested), compared to $1,963 for XTLB. Over the past 12 months, AEYE leads with a -27.9% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors AEYE at 6.4% vs XTLB's -18.4% — a key indicator of consistent wealth creation.
| Metric | XTLBXTL Biopharmaceut… | AEYEAudioEye, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +11.3% | -18.7% |
| 1-Year ReturnPast 12 months | -50.9% | -27.9% |
| 3-Year ReturnCumulative with dividends | -45.7% | +20.6% |
| 5-Year ReturnCumulative with dividends | -80.4% | -60.2% |
| 10-Year ReturnCumulative with dividends | -87.3% | +102.2% |
| CAGR (3Y)Annualised 3-year return | -18.4% | +6.4% |
AEYE leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — XTLB and AEYE each lead in 1 of 2 comparable metrics.
Risk & Volatility
XTLB is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AEYE currently trades 49.4% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XTLBXTL Biopharmaceut… | AEYEAudioEye, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 2.29x |
| 52-Week HighHighest price in past year | $10.28 | $16.39 |
| 52-Week LowLowest price in past year | $1.05 | $5.31 |
| % of 52W HighCurrent price vs 52-week peak | +26.0% | +49.4% |
| RSI (14)Momentum oscillator 0–100 | 57.0 | 61.3 |
| Avg Volume (50D)Average daily shares traded | 2.4M | 194K |
Evenly matched — XTLB and AEYE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | XTLBXTL Biopharmaceut… | AEYEAudioEye, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AEYE leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XTLB leads in 1 (Valuation Metrics). 1 tied.
Best OverallAudioEye, Inc. (AEYE)Leads 3 of 6 categories
Loading custom metrics...
XTLB vs AEYE: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — XTLB or AEYE?
Over the past 5 years, AudioEye, Inc.
(AEYE) delivered a total return of -60. 2%, compared to -80. 4% for XTL Biopharmaceuticals Ltd. (XTLB). Over 10 years, the gap is even starker: AEYE returned +102. 2% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — XTLB or AEYE?
By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.
(XTLB) is the lower-risk stock at 1. 71β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 34% more volatile than XTLB relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 15% for AudioEye, Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — XTLB or AEYE?
AudioEye, Inc.
(AEYE) is the more profitable company, earning -7. 6% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — XTLB or AEYE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is XTLB or AEYE better for a retirement portfolio?
For long-horizon retirement investors, XTL Biopharmaceuticals Ltd.
(XTLB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. AudioEye, Inc. (AEYE) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTLB: -87. 3%, AEYE: +102. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between XTLB and AEYE?
These companies operate in different sectors (XTLB (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.